 Israel's competition authority says Bristol-Myers Squibb has agreed to pay $2.7 million to settle a potential case over its blocking of a generic version for anti-cancer drug Imnovid. The antitrust agency says that Bristol and Neopharm Scientific, the Israeli distributor of Imnovid, declined a request by KS Kim International for drug samples to make a copycat version of Imnovid.